EMA advises on transparency requirements of EU clinical trial regulation
Aims to balance information needs of patients with academia and industry
The European Medicines Agency (EMA) has released a paper explaining its consultation with the pharma industry on proposed transparency reforms to the European Union (EU) clinical trial regulation (Regulation No 536/2014). EMA wants feedback. Its goal is 'to balance carefully the information needs of patients and the public with the needs of academia and industry'.